Holiday Notification: Cayman Chemical will be closed Monday, May 28, 2012, in observance of the Memorial Day holiday.
More…
Please feel free to continue placing orders via our website or via fax at 734-971-3640. You may send an email to customer service at custserv@caymanchem.com , or to technical support at techserv@caymanchem.com which we will respond to the next business day. Cayman will resume regular business hours and shipping schedules on Tuesday, May 29, 2012. Thank you for your patience and understanding.
Melatonin, produced in the pineal gland, is an endogenous regulator of circadian rhythms. It acts through the melatonin receptors (MT1 and MT2) and has been shown to have anti-depressant activity in experimental models of clinical depression. Agomelatine is a metabolically stable analog of melatonin that displays agonist activity for MT1 and MT2 binding with nanomolar affinity.1 However, unlike melatonin, agomelatine is a competitive antagonist of human and porcine serotonin (5-HT2C) receptors (pKi = 6.2 and 6.4, respectively) as well as human 5-HT2B receptors (pKi = 6.6).2 Agomelatine abolishes 5-HT2C agonist effects both in cells and in vivo. It also dose dependently increases extracellular levels of noradrenaline and dopamine in frontal cortex of freely moving rats.2
1
Yous, S., Andrieux, J., Howell, H.E., et al. Novel naphthalenic ligands with high affinity for the melatonin receptor. J Med Chem35(8)1484-1486(1992).
2
Millan, M.J., Gobert, A., Lejeune, F., et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther306(3)954-964(2003).
Room temperature
in continental US; may vary elsewhere
SMILES
Copy SMILES to clipboard
COc1ccc2cccc(CCNC(=O)C)c2c1
Background Reading
Yous, S., Andrieux, J., Howell, H.E., et al. Novel naphthalenic ligands with high affinity for the melatonin receptor. J Med Chem35(8)1484-1486(1992).
Millan, M.J., Gobert, A., Lejeune, F., et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther306(3)954-964(2003).
Agomelatine is available in the following screening
library: